A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Mark Jones, MD
Incyte Corporation
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
129 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Facility name not stated
Camperdown, New South Wales, Australia
- Facility name not stated
Westmead, New South Wales, Australia
- Facility name not stated
Wollstonecraft, New South Wales, Australia
- Facility name not stated
Cairns, Queensland, Australia
- Facility name not stated
Greenslopes, Queensland, Australia
- Facility name not stated
Kurralta Park, South Australia, Australia
- Facility name not stated
Melbourne, Victoria, Australia
- Facility name not stated
Brussels, Belgium
- Facility name not stated
Ghent, Belgium
- Facility name not stated
North Vancouver, British Columbia, Canada
- Facility name not stated
Ottawa, Ontario, Canada
- Facility name not stated
Toronto, Ontario, Canada
- Facility name not stated
Montreal, Quebec, Canada
- Facility name not stated
Santiago, Chile
- Facility name not stated
Viña del Mar, Chile
- Facility name not stated
Aarhus, Denmark
- Facility name not stated
Herlev, Denmark
- Facility name not stated
Odense C, Denmark
- Facility name not stated
Bordeaux, France
- Facility name not stated
Lille, France
- Facility name not stated
Marseille, France
- Facility name not stated
Paris, France
- Facility name not stated
Pierre-Bénite, France
- Facility name not stated
Reims, France
- Facility name not stated
Rennes, France
- Facility name not stated
Toulouse, France
- Facility name not stated
Villejuif, France
- Facility name not stated
Buxtehude, Germany
- Facility name not stated
Essen, Germany
- Facility name not stated
Hanover, Germany
- Facility name not stated
Kiel, Germany
- Facility name not stated
Tübingen, Germany
- Facility name not stated
Cork, Ireland
- Facility name not stated
Dublin, Ireland
- Facility name not stated
Galway, Ireland
- Facility name not stated
Ramat Gan, Israel
- Facility name not stated
Bergamo, Italy
- Facility name not stated
Genova, Italy
- Facility name not stated
Milan, Italy
- Facility name not stated
Naples, Italy
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 21 Jun 2016
- Primary completion
- 8 Jan 2018
- Completion
- 16 Aug 2019
- Last update posted
- 24 Aug 2025
- Registered enrollment
- 706
- Registry id
- NCT02752074
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.